Profil Penderita Covid-19 dengan Komorbid Penyakit Jantung Koroner di Rumah Sakit Umum Haji Surabaya
Keywords:COVID-19, comorbidity, coronary heart disease
Background : COVID-19 is an illness caused by a new version of corona virus that still has connections with the family of SARS virus. COVID-19 first emerged in Wuhan and spread through contaminated individual contact, droplets, fomites. COVID-19 appear in Indonesia on 2020. Risk factor of COVID-19 exposure is comorbidity like heart disease. Coronary heart disease is a chronical inflammation characterized by the narrowing of coronary artery supplying oxygen. Coronary heart disease as comorbidity, worsens the clinical conditions of COVID-19 patients.
Method : This is descriptive research with approach of quantitive method using secondary data. Population are medical records of COVID-19 patients with coronary heart disease comorbid ity in Haji Surabaya Public Hospital on 1st June 2020 to 31st August 2021. Total sampling is used in which all samples are included if in accordance to inclusion criteria in certain periods of time. Variables include age, gender, blood pressure, temperature, BMI, hemoglobin, RBC, WBC, platelet, hematokrit, PPT, aPTT, D-dimer, ECG. Collected data are analyzed descriptively and presented in tables.
Results : Research shows COVID-19 patients with coronary heart disease comorbidity profile in Haji Public Hospital Surabaya often happens to age range of 56 – 65 years old, often in man, with normal vital signs. BMI affected fragility of exposure and risk factor of COVID-19 as well as coronary heart disease. CBC shows normal score rate and PPT, APTT majority normal. Abnormality in d-dimer status of patients increased, indicating increase in coagulation activity, abnormality in ECG interpretation shows abnormality of heart functions.
Cassar, A. et al. (2009) ‘Chronic coronary artery disease: Diagnosis and management’, Mayo Clinic Proceedings, 84(12), pp. 1130–1146. doi: 10.4065/mcp.2009.0391.
Chowdhury, S. D. and Oommen, A. M. (2020) ‘Epidemiology of COVID-19’, pp. 3–7.
Clerkin, K. J. et al. (2020) ‘COVID-19 and Cardiovascular Disease’, Circulation, 2019, pp. 1648–1655. doi: 10.1161/CIRCULATIONAHA.120.046941.
Coronavirus disease (COVID-19) (no date). Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19#:~:text=symptoms (Accessed: 1 August 2021).
Ghani, L., Susilawati, M. D. and Novriani, H. (2016) ‘Faktor Risiko Dominan Penyakit Jantung Koroner di Indonesia’, Buletin Penelitian Kesehatan, 44(3), pp. 153–164. doi: 10.22435/bpk.v44i3.5436.153-164.
Guan, W. J. et al. (2020) ‘Cardiovascular comorbidity and its impact on patients with COVID-19’, European Respiratory Journal, 55(6). doi: 10.1183/13993003.01227-2020.
Huang, C. et al. (2020) ‘Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China’, The Lancet, 395(10223), pp. 497–506. doi: 10.1016/S0140-6736(20)30183-5.
Huang, G., Kovalic, A. J. and Graber, C. J. (2020) ‘Prognostic value of leukocytosis and lymphopenia for coronavirus disease severity’, Emerging Infectious Diseases, 26(8), pp. 1839–1841. doi: 10.3201/eid2608.201160.
Indonesia: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data (no date). Available at: https://covid19.who.int/region/searo/country/id (Accessed: 1 August 2021).
Kementerian Kesehatan Republik Indonesia (no date). Available at: https://www.kemkes.go.id/index.php?txtKeyword=status+gizi&act=search-by-map&pgnumber=0&charindex=&strucid=1280&fullcontent=1&C-ALL=1 (Accessed: 27 September 2021).
Liang, C. et al. (2021) ‘Coronary heart disease and COVID-19 : A meta-analysis’, 156, pp. 547–554.
Libby, P. and Theroux, P. (2005) ‘Pathophysiology of coronary artery disease’, Circulation, 111(25), pp. 3481–3488. doi: 10.1161/CIRCULATIONAHA.105.537878.
Liu, K. et al. (2020) ‘Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients’, Journal of Infection, 80(6), pp. e14–e18. doi: 10.1016/j.jinf.2020.03.005.
Lowe, G. D. O. (2005) ‘Fibrin D-Dimer and Cardiovascular Risk’.
Parasher, A. (2021) ‘COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment’, Postgraduate Medical Journal, 97(1147), pp. 312–320. doi: 10.1136/postgradmedj-2020-138577.
Pooling, T. H. E. (1978) ‘RELATIONSHIP OF BLOOD PRESSURE , SERUM CHOLESTEROL , SMOKING HABIT , RELATIVE WEIGHT AND ECG ABNORMALITIES TO INCIDENCE OF MAJOR CORONARY EVENTS : FINAL REPORT OF THE POOLING PROJECT’, 31, pp. 201–306.
Pourbagheri-sigaroodi, A. et al. (2020) ‘Clinica Chimica Acta Laboratory fi ndings in COVID-19 diagnosis and prognosis’, 510(August), pp. 475–482.
Unicef, WHO and IFRC (2020) ‘Key Messages and Actions for Prevention and Control in Schools’, Key Messages and Actions for COVID-19 Prevention and Control in Schools, (March), p. 13. Available at: https://www.who.int/docs/default-source/coronaviruse/key-messages-and-actions-for-covid-19-prevention-and-control-in-schools-march-2020.pdf?sfvrsn=baf81d52_4#:~:text=COVID-19 is a,2019-nCoV.’.
Yustinawati, R. and Achadi, A. (2020) ‘RISK FACTORS FOR MORTALITY IN PATIENTS WITH COVID-19 : A SYSTEMATIC REVIEW The 7th International Conference on Public Health Solo , Indonesia , November 18-19 , 2020 | 1 The 7th International Conference on Public Health Solo , Indonesia , November 18-19 ’, pp. 1–11.
Zhang, S. fen et al. (2018) ‘Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou’, PLoS ONE, 13(1), pp. 1–20. doi: 10.1371/journal.pone.0191789.